^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | zotatifin (eFT226) (eIF4A1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
B109 - Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation
Published date:
10/28/2019
Excerpt:
Solid tumor xenograft models harboring FGFR1/2 or HER2 amplifications treated with eFT226 resulted in significant in vivo tumor growth inhibition and regression at well tolerated doses in breast, non-small cell lung and colorectal cancer models.
